Cassidy Bio
Tel Aviv, Israel· Est.
AI‑powered genome‑editing design platform that turns years of trial‑and‑error into days of predictive, therapeutic‑grade gene‑therapy engineering.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered genome‑editing design platform that turns years of trial‑and‑error into days of predictive, therapeutic‑grade gene‑therapy engineering.
Rare diseasesHematologyOncology
Technology Platform
A genomic foundation model trained on 70,000 diverse human genomes that predicts guide RNA efficacy, safety, repair outcomes, and delivery context for CRISPR and base‑editing therapies.
Opportunities
Growing demand for rapid, AI‑driven gene‑editing design creates a sizable market for platform services across biotech and pharma.
Risk Factors
Reliance on model validation and regulatory acceptance of in‑silico predictions could delay adoption.
Competitive Landscape
Competes with AI‑bioinformatics firms and traditional CRISPR design services; differentiates via end‑to‑end predictive confidence and a closed‑loop wet‑lab feedback system.